| Combination of CTLA-4 and PD-1 blockers for treatment of cancer |
80 |
| Advances in cancer immunotherapy 2019-latest trends |
72 |
| Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-beta 1 |
66 |
| STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review |
61 |
| Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis |
60 |
| Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype |
57 |
| LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling |
56 |
| Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis |
56 |
| Long noncoding RNA AFAP1-AS1 acts as a competing endogenous RNA of miR-423-5p to facilitate nasopharyngeal carcinoma metastasis through regulating the Rho/Rac pathway |
54 |
| CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1-dependent activation of -catenin pathway |
50 |
| MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer |
49 |
| Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology |
48 |
| CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth |
47 |
| RNA sequencing reveals the expression profiles of circRNA and indicates that circDDX17 acts as a tumor suppressor in colorectal cancer |
46 |
| Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA |
42 |
| New therapeutic strategies to treat human cancers expressing mutant p53 proteins |
42 |
| SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88 |
41 |
| Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts |
41 |
| Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway |
41 |
| Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression |
40 |
| Role of metabolism in cancer cell radioresistance and radiosensitization methods |
40 |
| Cancer DNA vaccines: current preclinical and clinical developments and future perspectives |
40 |
| circFBLIM1 act as a ceRNA to promote hepatocellular cancer progression by sponging miR-346 |
37 |
| circPTN sponges miR-145-5p/miR-330-5p to promote proliferation and stemness in glioma |
36 |
| Classification of triple-negative breast cancers based on Immunogenomic profiling |
36 |
| FUS/circ_002136/miR-138-5p/SOX13 feedback loop regulates angiogenesis in Glioma |
36 |
| The role of cellular reactive oxygen species in cancer chemotherapy |
35 |
| ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway |
34 |
| SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma |
33 |
| HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regulating miR-186-5p and PIK3R3 |
33 |
| Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-beta signaling pathway |
33 |
| Clinical development of targeted and immune based anti-cancer therapies |
33 |
| Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis |
32 |
| Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways |
32 |
| Knockdown of circDENND4C inhibits glycolysis, migration and invasion by up-regulating miR-200b/c in breast cancer under hypoxia |
31 |
| Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma |
31 |
| Long non-coding RNA AGAP2-AS functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma |
31 |
| LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells |
31 |
| Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme |
31 |
| Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/beta-catenin pathway |
31 |
| Exosomal miR-9 inhibits angiogenesis by targeting MDK and regulating PDK/AKT pathway in nasopharyngeal carcinoma |
30 |
| The roles of glucose metabolic reprogramming in chemo- and radio-resistance |
30 |
| MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma |
30 |
| Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities |
29 |
| Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway |
29 |
| Long noncoding RNA MIR31HG inhibits hepatocellular carcinoma proliferation and metastasis by sponging microRNA-575 to modulate ST7L expression |
29 |
| HIF-2 alpha promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways |
29 |
| Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling |
29 |
| Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells |
28 |
| From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma |
28 |
